LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2020 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.